- $69.98bn
- $74.26bn
- $276.71bn
- 69
- 52
- 97
- 85
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 214,319 | 231,051 | 238,228 | 263,966 | 276,711 |
Cost of Revenue | |||||
Gross Profit | 11,754 | 12,023 | 12,284 | 13,286 | 12,358 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 213,543 | 228,148 | 243,268 | 262,119 | 272,330 |
Operating Profit | 776 | 2,903 | -5,040 | 1,847 | 4,381 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 610 | 1,144 | -5,034 | 1,928 | 4,630 |
Provision for Income Taxes | |||||
Net Income After Taxes | 168 | 1,126 | -4,339 | 1,292 | 3,725 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 34 | 900 | -4,539 | 1,114 | 3,560 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 34 | 900 | -4,539 | 1,114 | 3,560 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 7.72 | 6.13 | 7.05 | 13.4 | 26.4 |
Dividends per Share |